Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repeat-dose incobotulinumtoxinA for combined treatment of upper facial lines
2014-003770-16Phase 3Completed
- Sponsor
- Merz
- Start
- Jan 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of botulinum toxin type A in rhytides, upper facial lines, Forehead lines and 1 more, sponsored by Merz. Primary endpoint: Safety and tolerability of repeat-dose incobotulinumtoxinA. Started Jan 2015; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
rhytidesupper facial linesForehead linesglabellar furrowing
Beyond the preview
Go deeper on 2014-003770-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003770-16.